Pharma is claiming that it spends all its money on R&D, but it won't show us the books.

How much time is remaining, Mr. Chairman? The Acting CHAIR. The gentleman has 2 minutes remaining.

As I mentioned earlier, we just have a difference of opinion. We think the Affordable Care Act is important to preserve and important to improve. My colleagues, when they have had an opportunity, have voted to repeal it. Failing to repeal…

This legislation is going to help make healthcare more affordable and more accessible. There are two things: One, we finally are attacking the explosion in the cost of prescription drugs, and I thank my Republican colleagues for…

I have an amendment at the desk. The Acting CHAIR. The Clerk will designate the amendment. The text of the amendment is as follows: Add at the end of title II the following new section: SEC. 205. PROTECTION OF HEALTH INSURANCE COVERAGE IN…

they are fiction. They really are.

But we know that 25 million Americans currently lack access to broadband.

But you, I think, have answered my question that it is not new money.

But my point is this was--this was presented to the public as a big deal.

I thank the gentleman for yielding. Mr. Chairman, if we want to level with the American people, let's acknowledge something: We have a difference of opinion on healthcare. When we passed the Affordable Care Act, it provided, for the first…

I want to thank the panel, and I want to thank you, Madam Chair, and I will yield back the 30 seconds I have.

the pharmaceutical industry creates life-saving and -extending drugs and pain-relieving drugs. That is a good thing. You are killing us with the price and that is on both sides--both sides--and we are trying to get to the bottom of this.

It really is bizarre what happens.

All of us have a concern about a formulary. Is that going to restrict patient access?

Now, I am proud of the bipartisan work but it is critical that we recognize that the work cannot and will not stop there.

I don't see that as R&D.

Solving this drug-pricing crisis will require a multifaceted approach that addresses the misaligned incentives throughout the supply chain that often encourage gaming and lead to higher costs.

There ought to be transparency--transparency on the rebates and, I think, transparency on how much is really spent on R&D.

One of the things that he talked about was drug importation, and, obviously, this would have to be safe.

The standards have made a difference. You know, there are about 2.7 billion lightbulb sockets where, if we use those, it is going to save homeowners about 100 bucks a year.

However, as newer and more specialized medicines come to market, these drugs typically have much higher prices that are too often just simply unaffordable.

It cost taxpayers $500 million--500 million bucks.

My view is the safety issue is a red herring because I haven't heard anybody anywhere who is in favor of unsafe products.

How essential are they, and how can we provide them?

I endorse everything that my colleague, Mr. Griffith, said, and appreciate you being willing to work with him.